Tuesday, September 30, 2025 at 12-1pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Cost Effectiveness Evaluation of Covalent Bruton's Tyrosine Inhibitor Treatments Among Medicare Patients with Chronic Lymphocytic Leukemia (CLL)

Program Description

Chronic Lymphocytic Leukemia (CLL) is a complex, indolent blood cancer in which immature lymphocytes are found mostly in the blood and bone marrow.¹  It is the most common type of leukemia in adults, affecting an estimated 226,432 people in the United States as of 2022.^2,3 The entry of Bruton’s tyrosine kinase inhibitors (BTKis) into the treatment landscape caused a shift to more targeted oral therapy .⁴ The cost of treatment and medically managing CLL patients within the US healthcare system is of particular interest for healthcare decision makers.⁵  The objective of this webinar is to explore the results of a cost-effectiveness analyses of covalent BTKis in first-line (1L) or relapsed/refractory (R/R) settings using data from clinical trials and the US Medicare perspective.⁶

Learning Objectives

• Review the current clinical and economic inputs that informed the cBTKi cost-effectiveness analysis in 1L and R/R CLL.
• Understand how a Semi-Markov model was used to estimate clinical outcomes, AEs, and costs of covalent BTKis.
• Consider cBTKi cost-effectiveness within this model and identify which factors primarily drive the total cost of care.

The following content is approved for use with a limited audience of payers, formulary committees, and other similar entities.
There are no head-to-head studies in the 1L setting, and this economic study was not designed to draw any conclusions regarding efficacy and safety.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.

References:

1. CLL. National Cancer Institute. Accessed June 25, 2025. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cll
2. Chronic lymphocytic leukemia. National Organization for Rare Disorders. Accessed June 25, 2025. https://rarediseases.org/rare-diseases/chronic-lymphocytic-leukemia/
3. Cancer stat facts: leukemia – chronic lymphocytic leukemia (CLL). National Cancer Institute. Accessed June 25, 2025. https://seer.cancer.gov/statfacts/html/clyl.html
4. Desikan SP, et al. Expert Rev Hematol. 2022; 15(5):403–409
5. Hilal, T., et al. Economic impact of oral therapies for chronic lymphocytic leukemia—the burden of novelty. Curr Hematol Malig Rep. 2018; 13: 237-243.
6. Crawford S, Li H, Srivastava B, et al. Cost-effectiveness evaluation of Bruton tyrosine kinase inhibitor (BTKi) treatments among Medicare patients with chronic lymphocytic leukemia (CLL) first-line (1L) and relapsed/refractory (R/R) settings [poster]. Presented at the National Comprehensive Cancer Network (NCCN) 2025 Annual Conference; March 28-30, 2025; Orlando, FL.